Tobacco Patterns and Risk of Chronic Obstructive Pulmonary Disease: Results From a Cross-Sectional Study

Research Projects

Organizational Units

Journal Issue

Abstract

Introduction There is still uncertainty about which aspects of cigarette smoking influence the risk of Chronic Obstructive Pulmonary Disease (COPD). The aim of this study was to estimate the COPD risk as related to duration of use, intensity of use, lifetime tobacco consumption, age of smoking initiation and years of abstinence. Methods We conducted an analytical cross-sectional study based on data from the EPISCAN-II study (n = 9092). All participants underwent a face-to-face interview and post-bronchodilator spirometry was performed. COPD was defined as post-bronchodilator FEV1/FVC < 70%. Parametric and nonparametric logistic regression models with generalized additive models were used. Results 8819 persons were included; 858 with COPD and 7961 without COPD. The COPD risk increased with smoking duration up to ≥50 years [OR 3.5 (95% CI: 2.3–5.4)], with smoking intensity up to ≥39 cig/day [OR 10.1 (95% CI: 5.3–18.4)] and with lifetime tobacco consumption up to >29 pack-years [OR 3.8 (95% CI: 3.1–4.8)]. The COPD risk for those who started smoking at 22 or later was 0.9 (95% CI: 0.6–1.4). The risk of COPD decreased with increasing years of cessation. In comparison with both never smokers and current smokers, the lowest risk of COPD was found after 15–25 years of abstinence. Conclusion COPD risk increases with duration, intensity, and lifetime tobacco consumption and decreases importantly with years of abstinence. Age at smoking initiation shows no effect. After 15–25 years of cessation, COPD risk could be equal to that of a never smoker. This work suggests that the time it takes to develop COPD in a smoker is about 30 years

Description

Bibliographic citation

Archivos de Bronconeumología 59 (2023) 717–724

Relation

Has part

Has version

Is based on

Is part of

Is referenced by

Is version of

Requires

Sponsors

The EPISCAN II study was funded and sponsored by GlaxoSmithKline, Spain through an unrestricted grant. The EPISCAN II study is registered in ClinicalTrial.gov under registry number: NCT01122758. Dr. Ahluwalia funded in part by P20GM130414, a NIH funded Center of Biomedical Research Excellence (COBRE). The sponsors were not involved in study design, data collection, analysis and interpretation, or original report writing

Rights

© 2023 The Authors. Published by Elsevier España, S.L.U. on behalf of SEPAR. This is an open access article under the CC BY-NC-ND license (http://creativecommons. org/licenses/by-nc-nd/4.0/)
Attribution-NonCommercial-NoDerivatives 4.0 Internacional